Avandamet Bioequivalence Study Brazil - Fed Administration

Assessment of Relative Bioavailability of Avandamet 4 mg + 1000 mg (GSK) in the Form of Film Coated Tablets Versus Avandamet 2 mg + 500 mg (GSK) in the Form of Film Coated Tablets, in Healthy Volunteers After Feeding Standardized, Using Liquid Chromatography.

The study is prospective, open-label, randomized, crossover, with 02 treatments, 02 sequences, and 02 periods. The volunteers received, in each period, the reference or the test formulation after standardized meals.

Study Overview

• Status: Completed
• Conditions: Diabetes Mellitus, Type 2
• Intervention / Treatment: Drug: Rosiglitazone Maleate + Metformin 4 miligrams (mg) + 1000 mg; Drug: Rosiglitazone Maleate + Metformin 2 miligrams (mg) + 500 mg

Detailed Description

This is an open-label, randomized, crossover study with 02 treatments, 02 sequences, and 02 periods, in which the healthy volunteers received, in each period, the test or the reference formulation after standardized meals. Test product is Rosiglitazone Maleate + Metformin - Avandamet 4 mg + 1000 mg (GlaxoSmithKline Brasil Ltda) in the form of film coated tablets. Reference product is Rosiglitazone Maleate + Metformin - Avandamet 2 mg + 500 mg (Glaxo Smith Kline Brasil Ltda) in the form of film coated tablets. The population is composed by 26 healthy volunteers, adults, of both genders and their ages varied between 18 and 50 years. Their body mass index (BMI) varied between 18,5 and 25. There are no restrictions regarding the ethnic group. The relative bioavailability of the two formulations, after oral administration, will be evaluated based on statistical comparisons of relevant pharmacokinetic parameters obtained from data of drug concentration in blood.

• Study Type: Interventional
• Enrollment (Actual): 26
• Phase: Phase 1

Contacts and Locations

Study Locations

• Brazil
  • Goiás
    • Goiania, Goiás, Brazil
      • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

EXCLUSION CRITERIA:

• The volunteer has a known hypersensitivity to the study drug or to compounds chemically related;
• History or presence of hepatic or gastrointestinal illnesses, or other condition that interferes over the drug's absorption, distribution, excretion or metabolism;
• History of neurological, endocrine, pulmonary, hamatologic, immune, brain, metabolic or cardiovascular illness;
• Hypo or hypertension of any etiologic that needs pharmacologic treatment;
• The results of the laboratory exams are out of the values considered as normal according this protocol's rules, unless that they are considered as clinically irrelevant by the investigator;
• Has history of alcohol or drugs abuse;
• History of use drug inducing and/or inhibitors of hepatic metabolism within 30 days prior to drug study administration;
• Use of MAO inhibitors two weeks before the start of treatment; - Use of inhibitors of 5-TH reuptake,
• Pregnancy or breastfeeding,
• Smoking;
• Use of regular medication within 4 weeks prior to study iniciation;
• Use of experimental drug or participation in any clinical study within 6 months prior to study iniciation.

INCLUSION CRITERIA:

• Age between 18 and 50 years;
• Body mass index ≥ 18,5 and ≤25,0, can vary up to 15% for the upper limit (18,5 to 28,75);
• Good health conditions;
• Obtain the Informed Consent's signed.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Avandamet test product; Test product: Avandamet (Rosiglitazone Maleate + Metformin) 4 miligrams (mg) + 1000 mg in Period 1, followed by a 7-day washout period during which no medication was administered, followed by reference product: Avandamet (Rosiglitazone Maleate + Metformin) 2 mg + 500 mg in Period 2	Drug: Rosiglitazone Maleate + Metformin 4 miligrams (mg) + 1000 mg; Avandamet test product
Active Comparator: Avandamet reference product; Reference product: Avandamet (Rosiglitazone Maleate + Metformin) 2 miligrams (mg) + 500 mg in Period 1; followed by a 7-day washout period during which no medication was administered; followed by test product: Avandamet (Rosiglitazone Maleate + Metformin) 4 mg + 1000 mg in Period 2	Drug: Rosiglitazone Maleate + Metformin 2 miligrams (mg) + 500 mg; Avandamet reference product

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUC0-t of Rosiglitazone Maleate	The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC 0-t is calculated from time 0 (prior to administration of medication) to time t (the time of the last quantifiable concentration). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. ng, nanograms; ml, milliliter.	Day 1 (day that blood collection started) and Day 2 (Period 1) and Days 8 and 9 (Period 2)
Cmax of Rosiglitazone Maleate	Cmax is defined as the maximum or "peak" concentration of a drug observed after its administration. Cmax is one of the parameters of particular use in estimating the bioavailability of drugs, by measuring the total amount of drug absorbed.	Day 1 (day that blood collection started) and Day 2 (Period 1) and Days 8 and 9 (Period 2)
AUC0-infinity of Rosiglitazone Maleate	The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.	Day 1 (day that blood collection started) and Day 2 (Period 1) and Days 8 and 9 (Period 2)
AUC0-t of Metformin Hydrochloride	The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-t is calculated from time 0 (prior to administration of medication) to time t (the time of the last quantifiable concentration). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. ng, nanograms; ml, milliliter.	Day 1 (day that blood collection started) and Day 2 (Period 1) and Days 8 and 9 (Period 2)
AUC0-infinity of Metformin Hydrochloride	The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.	Day 1 (day that blood collection started) and Day 2 (Period 1) and Days 8 and 9 (Period 2)
Cmax of Metformin Hydrochloride	Cmax is defined as the maximum or "peak" concentration of a drug observed after its administration. Cmax is one of the parameters of particular use in estimating the bioavailability of drugs, by measuring the total amount of drug absorbed.	Day 1 (day that blood collection started) and Day 2 (Period 1) and Days 8 and 9 (Period 2)

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Study record dates

Study Major Dates

• Study Start (Actual): November 24, 2009
• Primary Completion (Actual): December 6, 2009
• Study Completion (Actual): December 6, 2009

Study Registration Dates

• First Submitted: August 31, 2010
• First Submitted That Met QC Criteria: March 17, 2011
• First Posted (Estimate): April 8, 2011

Study Record Updates

• Last Update Posted (Actual): July 12, 2017
• Last Update Submitted That Met QC Criteria: June 14, 2017
• Last Verified: June 1, 2017

More Information

Terms related to this study

• Keywords: Healthy volunteers; Metformin; Rosiglitazone; Avandamet; Fed conditions; Bioequivalence
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Metformin; Rosiglitazone; Maleic acid
• Other Study ID Numbers: 114040

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No